The In vitro and In vivo Effects of Re-Expressing Methylated von Hippel-Lindau Tumor Suppressor Gene in Clear Cell Renal Carcinoma with 5-Aza-2′-deoxycytidine
Open Access
- 15 October 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (20) , 7011-7021
- https://doi.org/10.1158/1078-0432.ccr-04-0516
Abstract
Purpose: Clear cell renal carcinoma (ccRCC) is strongly associated with loss of the von Hippel-Lindau (VHL) tumor suppressor gene. The VHL gene is functionally lost through hypermethylation in up to 19% of sporadic ccRCC cases. We theorized that re-expressing VHL silenced by methylation in ccRCC cells, using a hypo-methylating agent, may be an approach to treatment in patients with this type of cancer. We test the ability of two hypo-methylating agents to re-express VHL in cell culture and in mice bearing human ccRCC and evaluate the effects of re-expressed VHL in these models.Keywords
This publication has 52 references indexed in Scilit:
- Critical Role of Histone Methylation in Tumor Suppressor Gene Silencing in Colorectal CancerMolecular and Cellular Biology, 2003
- Role of transforming growth factor-alpha in von Hippel- Lindau (VHL)-/- clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesisProceedings of the National Academy of Sciences, 2001
- Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor ProteinJournal of Biological Chemistry, 2000
- Analysis of aberrant methylation of the VHL gene by transgenes, monochromosome transfer, and cell fusionOncogene, 1999
- Structure and Chromosomal Localization of the Human Prostasin (PRSS8) GeneGenomics, 1996
- Identification of the von Hippel-Lindau Disease Tumor Suppressor GeneScience, 1993
- The decomposition of 1-(.beta.-D-ribofuranosyl)-1,2-dihydropyrimidin-2-one (zebularine) in alkali: mechanism and productsThe Journal of Organic Chemistry, 1992
- Von Hippel–Lindau disease maps to the region of chromosome 3 associated with renal cell carcinomaNature, 1988
- The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomasEuropean Journal of Cancer and Clinical Oncology, 1987
- Comparison of the in vitro cytotoxicity (L1210) of 5-Aza-2′-deoxycytidine with its therapeutic and toxic effects in miceEuropean Journal of Cancer and Clinical Oncology, 1985